1 |
NCT01349062 |
Completed |
Traditional Complementary and Alternative Medicine (CAM) Therapy in the Treatment of HIV/AIDS |
|
- Drug: "Kallunk oxide (Immunotherapy) "
|
Interventional |
Phase 3 |
- Traditional Alternative Medicine Research, India
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy
- Viral Load Assay
- Absolute Immune Cells Count Assay(CD3, CD4, and CD8 + T cells)
- Prolonged Viral Suppression
|
1000 |
All |
8 Years to 45 Years (Child, Adult) |
NCT01349062 |
00276991 |
|
February 27, 2012 |
February 27, 2017 |
February 27, 2017 |
May 6, 2011 |
March 3, 2017 |
|
- Project Site Office, Near Sivan Kovil, Nallepily, Hospital of Integrated Research Site HIRS [new])
Palakkad, Kerala, India - Project Site Office, Hospital of Integrated Research Site HIRS(New), Karoor, Ambalapuzha-PO, Alleppey-District, Kerala, India 688561
Alleppey, India - Project Site Office, Hospital of Integrated Research Site HIRS(New), Ahammed Nagar, Mathura Nagar, Bhingar- PO
Mumbai, India
|
2 |
NCT01343654 |
Completed |
Text Messaging Intervention to Improve HIV Adherence in Rural Drug Users |
|
- Behavioral: Text messaging plus EMA
- Behavioral: Treatment as usual
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Missed Visit Proportion (MVP)
- pharmacy refill data
- Secondary: text messaged adherence and drug use data
|
54 |
All |
18 Years and older (Adult, Senior) |
NCT01343654 |
15475 |
TEXTR34 |
May 2011 |
September 2013 |
December 2013 |
April 28, 2011 |
February 15, 2018 |
|
- UVA Infectious Diseases Clinic
Charlottesville, Virginia, United States
|
3 |
NCT01338025 |
Terminated Has Results |
Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy |
|
- Drug: HAART regimen
- Drug: 3TC or FTC monotherapy
|
Interventional |
Phase 4 |
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- National Institute of Allergy and Infectious Diseases (NIAID)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Immunologic Deterioration
- Change in CD4+ T Cell Count
- Change in HIV-1 RNA Levels
- Number of Participants Non-adherent as Measured by 3-day Recall
|
33 |
All |
8 Years to 24 Years (Child, Adult) |
NCT01338025 |
IMPAACT P1094 U01AI068632 |
P1094 |
March 2011 |
May 2013 |
May 2013 |
April 19, 2011 |
November 13, 2015 |
May 23, 2014 |
- Univ. of California San Francisco NICHD CRS (5091)
San Francisco,, California, United States - Children's National Med. Ctr. Washington DC NICHD CRS (5015)
Washington, District of Columbia, United States - University of Florida (5051)
Jacksonville, Florida, United States - (and 14 more...)
|
4 |
NCT01337583 |
Withdrawn |
A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa |
|
- Other: Dapivirine
- Other: Placebo
- Drug: Dapivirine
|
Interventional |
Phase 3 |
- International Partnership for Microbicides, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Efficacy as determined by HIV-1 seroconversion rate per person-years of product use, measured at the end of the investigational product use period.
- Safety as determined by grade 3 and 4 AE's, clinically significant grade 2 laboratory findings (based on DAIDS grading) and all serious AE's.
- Adherence to the protocol-specific product regimen as determined by self-reported diary cards and questionnaires.
- The incidence of curable STI's or pregnancy as determined by STI testing and pregnancy testing.
|
0 |
Female |
18 Years to 40 Years (Adult) |
NCT01337583 |
IPM 009B |
|
July 2011 |
July 2014 |
July 2014 |
April 19, 2011 |
June 11, 2012 |
|
- Suba District Hospital
Mbita, Kenya - University of North Carolina Project
Lilongwe, Malawi - Desmond Tutu HIV Foundation, Nyanga (DTHF)
Nyanga, Cape Town, South Africa - (and 2 more...)
|
5 |
NCT01337570 |
Withdrawn |
A Safety and Efficacy Trial of Dapivirine Vaginal Ring in Africa |
|
- Other: Dapivirine
- Other: Placebo
- Drug: Dapivirine
|
Interventional |
Phase 3 |
- International Partnership for Microbicides, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Efficacy as determined by the proportion of women in each arm HIV-1 seroconversion rate per person-years of product use, measured at the end of the investigational product use period.
- Safety as determined by grade 3 and 4 AE's, clinically significant grade 2 laboratory findings (based on DAIDS grading) and all serious AE's.
- Adherence to the protocol-specific product regimen as determined by self-reported diary cards and questionnaires.
- The incidence of curable STI's or pregnancy as determined by STI testing and pregnancy testing.
|
0 |
Female |
18 Years to 40 Years (Adult) |
NCT01337570 |
IPM 009A |
|
July 2011 |
July 2014 |
July 2014 |
April 19, 2011 |
June 11, 2012 |
|
- College of Medicine - Johns Hopkins Project (JHP)
Blantyre, Malawi - African University Clinical Research Centre
Kigali, Rwanda - Qhakaza Mbokodo
Ladysmith, KwaZulu Natal, South Africa - (and 2 more...)
|
6 |
NCT01335191 |
Completed Has Results |
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001) |
|
- Biological: TUTI-16 (1.0 mg)
- Other: Placebo
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
27 |
All |
18 Years to 50 Years (Adult) |
NCT01335191 |
THYMON-11001 |
|
June 2011 |
June 2012 |
June 2012 |
April 14, 2011 |
February 15, 2013 |
February 15, 2013 |
- Clinilabs
New York, New York, United States
|
7 |
NCT01344941 |
Completed |
Human Immune Responses Toward HIV-1 Envelope Antigens |
|
|
Observational |
|
- St. Jude Children's Research Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Specific B cell and T cell responses in humans who received St Jude HIV-1 Vaccine
- Mechanism of HIV-1 envelope processing B cell and T cell activities
|
8 |
All |
18 Years and older (Adult, Senior) |
NCT01344941 |
XPD09-022 HIVBLD |
HIVBLD |
March 2010 |
November 2015 |
November 2015 |
April 29, 2011 |
November 5, 2015 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
8 |
NCT01340196 |
Completed Has Results |
Drug Drug Interaction of BI 201335 and Tenofovir |
|
- Drug: tenofovir/BI 201335
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Steady-state Pharmacokinetics of AUC0-24 of Tenofovir on Day 7 and on Day 15
- Steady-state Pharmacokinetics of Cmax of Tenofovir on Day 7 and on Day 15
- Steady-state Pharmacokinetics of C24hr of Tenofovir on Day 7 and on Day 15
- (and 5 more...)
|
16 |
All |
18 Years to 55 Years (Adult) |
NCT01340196 |
1220.50 |
|
April 2011 |
June 2011 |
|
April 22, 2011 |
July 31, 2015 |
July 31, 2015 |
- 1220.50.0001 Boehringer Ingelheim Investigational Site
Buffalo, New York, United States
|
9 |
NCT01343225 |
Unknown † |
Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection |
|
- Drug: atripla
- Drug: darunavir ritonavir raltegravir
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Vitamin D levels and bone density
- viral load and CD 4 count
|
40 |
All |
18 Years to 50 Years (Adult) |
NCT01343225 |
IISP # 38879 |
|
May 2011 |
May 2014 |
May 2014 |
April 28, 2011 |
April 28, 2011 |
|
|
10 |
NCT01348516 |
Completed |
Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023 |
- Human Immunodeficiency Virus
|
- Drug: KM-023
- Drug: Placebo for KM-023
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety/ Tolerability Evaluation
- Pharmacokinetic Evaluation of KM-023, Area under the plasma concentration versus time curve (AUC) of KM-023
- Pharmacokinetic Evaluation of KM-023, Peak Plasma Concentration (Cmax) of KM-023
|
83 |
All |
20 Years to 45 Years (Adult) |
NCT01348516 |
KMCP-023-101 |
|
May 2011 |
March 2012 |
|
May 5, 2011 |
July 26, 2012 |
|
- Clinical Trials Center, Seoul National University Hospital
Seoul, Korea, Republic of
|
11 |
NCT01350544 |
Completed Has Results |
Treatment Advocacy Intervention for HIV-Positive African Americans |
|
- Behavioral: Treatment Advocacy
|
Interventional |
Not Applicable |
- Boston Children’s Hospital
- National Institute on Minority Health and Health Disparities (NIMHD)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
|
216 |
All |
18 Years and older (Adult, Senior) |
NCT01350544 |
R01MD006058 |
TA |
April 2013 |
July 2015 |
December 2015 |
May 9, 2011 |
April 11, 2017 |
April 11, 2017 |
- AIDS Project Los Angeles
Los Angeles, California, United States
|
12 |
NCT01332565 |
Completed |
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects |
- Infection, Human Immunodeficiency Virus
|
|
Interventional |
Phase 1 |
- ViiV Healthcare
- Shionogi
- GlaxoSmithKline
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Plasma DTG pharmacokinetic parameters following single dose administration: area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC(0-t)).
- Plasma DTG pharmacokinetic parameters following single dose administration: area under the plasma concentration-time curve from time zero to infinity (AUC(0-∞)).
- Plasma DTG pharmacokinetic parameters following single dose administration: maximum observed concentration (Cmax).
- (and 8 more...)
|
10 |
All |
20 Years to 55 Years (Adult) |
NCT01332565 |
115381 |
|
April 2011 |
June 2011 |
June 2011 |
April 11, 2011 |
June 27, 2011 |
|
- GSK Investigational Site
Cypress, California, United States
|
13 |
NCT01336855 |
Recruiting |
Collection of Blood for Multiple Collaborative Studies |
|
|
Observational |
|
- University of California, San Francisco
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- All subjects will be asked detailed questions about their current health status and current sexual and drug use behavior. HIV positive subjects will additionally be asked specific to HIV-related conditions and treatment.
|
2000 |
All |
18 Years and older (Adult, Senior) |
NCT01336855 |
H8211-04743-22 |
|
January 1988 |
January 2020 |
January 2020 |
April 18, 2011 |
March 30, 2017 |
|
- San Francisco General Hospital
San Francisco, California, United States
|
14 |
NCT01347164 |
Completed |
Evaluation of a New HIV Prevention Intervention for Black Bisexually-active Men |
- Bisexually-active Men
- at Risk for HIV
|
- Behavioral: RISE life coaching intervention
- Behavioral: HIV Counseling
|
Interventional |
Phase 2 |
- Public Health Management Corporation
- Centers for Disease Control and Prevention
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
|
169 |
Male |
18 Years and older (Adult, Senior) |
NCT01347164 |
5UR6PS001099 |
RISE |
December 2010 |
June 2012 |
December 2012 |
May 4, 2011 |
April 17, 2018 |
|
- Public Health Management Corporation
Philadelphia, Pennsylvania, United States
|
15 |
NCT01348282 |
Completed |
Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study |
- Neurocognitive Disturbance
- HIV Infection
|
- Drug: Lithium
- Drug: Rivastigmine
|
Interventional |
Phase 4 |
- Fundacio Lluita Contra la SIDA
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of persons with neurocognitive impairment in the different study groups
- Adverse events associated with the initiation of therapy and toxicity parameters
- Emotional variables
- (and 3 more...)
|
33 |
All |
18 Years to 65 Years (Adult) |
NCT01348282 |
TRIANT-TE |
|
May 2011 |
March 2014 |
March 2014 |
May 5, 2011 |
April 1, 2014 |
|
- Fundació LLuita contra la SIDA
Badalona, Barcelona, Spain
|
16 |
NCT01346982 |
Completed |
Drug Interactions Between Silimarine and Darunavir/Ritonavir |
|
|
Interventional |
Phase 4 |
- Fundacio Lluita Contra la SIDA
- IrsiCaixa
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Area under the plasma concentration-time curve during the dosing interval (AUC0-12) of darunavir
- Area under the plasma concentration-time curve during the dosing interval (AUC0-12) of ritonavir
- Darunavir and ritonavir clearance (CL/F)
- (and 4 more...)
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT01346982 |
SILIDAR 2010-021159-25 |
|
March 2011 |
July 2011 |
July 2011 |
May 4, 2011 |
September 30, 2011 |
|
- Lluita contra la Sida Foundation, HIV Unit
Badalona, Barcelona, Spain
|
17 |
NCT01346878 |
Completed |
Antiretroviral Resistance Detection by Ultrasensitive Pyrosequencing of the HIV-1 Genome and Virological Response to Antiretroviral Rescue Treatment |
|
|
Observational |
|
- Fundacio Lluita Contra la SIDA
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Time to virological failure
- Proportion of patients with VL <50 and <200 copies
- Absolute decrease of viral load
- (and 4 more...)
|
143 |
All |
18 Years to 65 Years (Adult) |
NCT01346878 |
PRIUS-2 |
|
July 2010 |
April 2012 |
April 2012 |
May 3, 2011 |
October 25, 2012 |
|
- Laboratorio de Retrovirología irsiCaixa
Badalona, Barcelona, Spain - Mútua de Terrassa
Terrassa, Barcelona, Spain - Hospital Universitario San Cecilio
Granada, Spain - Hospital 12 de Octubre
Madrid, Spain
|
18 |
NCT01335698 |
Completed Has Results |
Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients |
|
- Drug: Atazanavir Sulphate
- Drug: Ritonavir
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants Who Died and With Adverse Events (AEs) Leading to Discontinuation, Hyperbilirubinemia, Jaundice, First-degree Arterioventricular Block, Tachycardia, and Rash
- Number of Participants With A Center of Disease Control and Prevention (CDC) Class C AIDS Event
- Number of Participants With Laboratory Test Results Meeting the Criteria for Grade 3-4 Abnormality
- (and 5 more...)
|
160 |
All |
3 Months to 11 Years (Child) |
NCT01335698 |
AI424-451 2010-024537-23 |
PRINCE2 |
May 27, 2011 |
September 10, 2014 |
January 22, 2018 |
April 14, 2011 |
March 1, 2018 |
February 8, 2016 |
- Children'S National Medical Center
Washington, District of Columbia, United States - SUNY Upstate Medical University
Syracuse, New York, United States - Local Institution
Buenos Aires, Bs As, Buenos Aires, Argentina - (and 29 more...)
|
19 |
NCT01338883 |
Completed |
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus |
|
- Drug: Cenicriviroc 100 mg
- Drug: Cenicriviroc 200 mg + Truvada
- Drug: Sustiva + Truvada
|
Interventional |
Phase 2 |
- Tobira Therapeutics, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- To determine the percentage of patients who achieve HIV-1 RNA levels below 50 copies/mL at Week 24
|
143 |
All |
18 Years and older (Adult, Senior) |
NCT01338883 |
TBR-652-2-202 |
|
June 2011 |
December 2012 |
June 2013 |
April 20, 2011 |
July 10, 2013 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Southwest Center for HIV / AIDS
Phoenix, Arizona, United States - AIDS Healthcare Foundation Research Center
Beverly Hills, California, United States - (and 45 more...)
|
20 |
NCT01332227 |
Completed Has Results |
Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1—Infected Patients |
|
- Drug: Atazanavir
- Drug: Ritonavir (heat-stable)
- Drug: Raltegravir
- Drug: Tenofovir/Emtricitabine
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With HIV-1 RNA Level <40 c/mL at Week 24
- Percentage of Participants With HIV-1 RNA Level <40 c/mL at Week 48
- Number of Participants With Virologic Rebound at Weeks 24 and 48
- (and 4 more...)
|
132 |
All |
18 Years and older (Adult, Senior) |
NCT01332227 |
AI424-402 2009-017032-41 |
SPARTAN |
October 2011 |
September 2013 |
February 2014 |
April 11, 2011 |
February 19, 2015 |
October 16, 2014 |
- Health For Life Clinic Pllc
Little Rock, Arkansas, United States - Eisenhower Medical Center
Palm Springs, California, United States - Metropolis Medical Pc
San Francisco, California, United States - (and 35 more...)
|
21 |
NCT01336829 |
Completed |
TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir. |
|
- Drug: ETR/telaprevir
- Drug: TMC278/telaprevir
- Drug: telaprevir/ETR
- Drug: telaprevir/TMC278
|
Interventional |
Phase 1 |
- Tibotec Pharmaceuticals, Ireland
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Bloodlevels of telaprevir following co-administration with ETR
- Bloodlevels of telaprevir following co-administration with TMC278
- Bloodlevels of ETR following co-administration with telaprevir
- (and 7 more...)
|
33 |
All |
18 Years to 55 Years (Adult) |
NCT01336829 |
CR017989 TMC125IFD1001 |
|
March 2011 |
September 2011 |
September 2011 |
April 18, 2011 |
August 29, 2012 |
|
|
22 |
NCT01345630 |
Terminated Has Results |
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1 |
|
- Drug: Maraviroc
- Drug: Emtricitabine/tenofovir
- Drug: darunavir/ritonavir 800/100 mg
- (and 2 more...)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL.
- Frequency of Adverse Events (AE).
- Number of Participants With Grade 3 or 4 AEs
- (and 22 more...)
|
813 |
All |
18 Years and older (Adult, Senior) |
NCT01345630 |
A4001095 2010-021785-30 |
MODERN |
September 2011 |
August 2013 |
January 2014 |
May 2, 2011 |
January 14, 2016 |
January 14, 2016 |
- University of Alabama at Birmingham - 1917 Research Clinic
Birmingham, Alabama, United States - Health Services Center
Hobson City, Alabama, United States - Kaiser Permanente
Hayward, California, United States - (and 174 more...)
|
23 |
NCT01340950 |
Completed |
Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China |
- HIV Infections
- Central Nervous System Diseases
- Dementia
|
- Drug: zidovudine-lamivudine-nevirapine
- Drug: tenofovir-lamivudine-efavirenz
|
Interventional |
Phase 4 |
- University of California, San Diego
- National Institute of Mental Health (NIMH)
- National Center for AIDS/STD Control and Prevention, China CDC
- (and 3 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Decline in neuropsychological performance at 96 weeks
|
250 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01340950 |
R01MH092225 1R01MH092225-01 |
|
July 2010 |
July 2014 |
July 2015 |
April 25, 2011 |
April 4, 2016 |
|
- Beijing Ditan Hospital
Beijing, Beijing, China - Beijing YouAn Hospital
Beijing, Beijing, China
|
24 |
NCT01335230 |
Completed Has Results |
The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients |
- HIV
- Hepatitis C, Chronic
- HCV Coinfection
|
|
Observational |
|
- University of Cincinnati
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Exploring the Role of Gut-associated Th17 in Microbial Translocation in HIV and HCV/HIV Coinfected Patients.
|
40 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01335230 |
UC 10110905 |
|
April 2011 |
January 2013 |
January 2013 |
April 14, 2011 |
September 11, 2015 |
August 5, 2014 |
- University of Cincinnati
Cincinnati, Ohio, United States
|
25 |
NCT01348308 |
Completed |
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients |
|
- Drug: Maraviroc (Celsentri)
- Drug: Placebo
|
Interventional |
Phase 3 |
- French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- Pfizer
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- To demonstrate the clinical benefit of the adjunction of Maraviroc to a combination of antiretroviral therapy defined as decrease of clinical events
- Safety evaluation and Clinical, Immunological and pharmacological evaluation
|
407 |
All |
18 Years and older (Adult, Senior) |
NCT01348308 |
2010-022293-14 ANRS 146 OPTIMAL |
OPTIMAL |
September 2011 |
March 2016 |
March 2016 |
May 5, 2011 |
July 12, 2016 |
|
- Hôpital Henri Mondor
Creteil, France
|
26 |
NCT01333826 |
Active, not recruiting |
Schooling, Income, and HIV Risk in Malawi |
- HIV
- Schooling
- Conditional Cash Transfers
- Unconditional Cash Transfers
|
- Behavioral: Zomba Cash Transfer Program
|
Interventional |
Not Applicable |
- George Washington University
- World Bank
- University of California, San Diego
- University of Malawi
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Sexually Transmitted Infections
- Schooling
- Marriage and fertility
- (and 2 more...)
|
3796 |
Female |
13 Years to 22 Years (Child, Adult) |
NCT01333826 |
KCP: RF-P109215-RESE-TF090932 RSB: RF-P109215-RESE-BBRSB |
SIHR |
September 2007 |
September 2012 |
May 2019 |
April 12, 2011 |
August 16, 2017 |
|
- Zomba District, Malawi
Zomba, Malawi
|
27 |
NCT01341626 |
Completed |
Juvenile Justice Girls Randomized Control Trial: Young Adult Follow-up |
|
- Behavioral: Treatment Foster Care (TFCO)
- Behavioral: Group Care
|
Interventional |
Phase 1 |
- Oregon Social Learning Center
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
- University of Oregon
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Delinquency
- substance use
- HIV risk behavior
- (and 2 more...)
|
166 |
Female |
13 Years to 18 Years (Child, Adult) |
NCT01341626 |
R01DA024672 R01DA015208 R01MH054257-01 R03MH091611 |
|
January 1997 |
December 2016 |
December 2016 |
April 26, 2011 |
April 24, 2017 |
|
- Oregon Social Learning Center
Eugene, Oregon, United States - University of Oregon
Eugene, Oregon, United States
|
28 |
NCT01334827 |
Completed |
A Formative Study to Explore the Sensory Perceptions of Vaginal Product Users |
- Microbicide Delivery System Acceptability
|
|
Observational |
|
- The Miriam Hospital
- ImQuest Pharmaceuticals, Inc.
- National Institute of Allergy and Infectious Diseases (NIAID)
|
Other / Industry / NIH |
|
- Qualitative User Perception Narratives
- User Perception Scale Scores
|
48 |
All |
18 Years and older (Adult, Senior) |
NCT01334827 |
11800 R33AI076967 |
Project MIST |
April 2011 |
June 2012 |
June 2012 |
April 13, 2011 |
September 28, 2012 |
|
- Miriam Hospital
Providence, Rhode Island, United States
|
29 |
NCT01334164 |
Completed |
Recovery Management Checkups for Women Offenders |
- Recovery Management Checkup (RMC)
- Outcome Monitoring
|
- Behavioral: Recovery Management Checkups
- Other: Outcome Monitoring
|
Interventional |
Phase 2 |
- Chestnut Health Systems
- Haymarket Center
- Cook County Sheriff's Women's Justice Services
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to treatment re-entry
- Any Treatment
- Abstinence
- HIV risk behaviors and Recidivism
|
480 |
Female |
18 Years and older (Adult, Senior) |
NCT01334164 |
1037-0905 R01DA021174 |
RMC-WO |
July 2007 |
June 2015 |
June 2015 |
April 13, 2011 |
July 29, 2015 |
|
- Chestnut Health Systems-Lighthouse Institute
Chicago, Illinois, United States - Chestnut Health Systems
Normal, Illinois, United States
|
30 |
NCT01334190 |
Completed |
A Prospective Observational Study of the Performance of Zarin in Kenya |
|
|
Observational |
|
- FHI 360
- United States Agency for International Development (USAID)
|
Other / U.S. Fed |
|
- The cumulative probability of pregnancy
- Prevalence and incidence rates of immediate and delayed complications associated with insertion or removal
- Prevalence and incidence rate of adverse events
- (and 3 more...)
|
602 |
Female |
18 Years to 44 Years (Adult) |
NCT01334190 |
10264 |
|
June 2011 |
February 2013 |
February 2013 |
April 13, 2011 |
July 2, 2013 |
|
|